We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

498 hedge funds and large institutions have $22.6B invested in Alnylam Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 96 funds opening new positions, 167 increasing their positions, 160 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more first-time investments, than exits

New positions opened: 96 | Existing positions closed: 44

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

10% more funds holding

Funds holding: 452 → 498 (+46)

8% more capital invested

Capital invested by funds: $20.9B → $22.6B (+$1.71B)

4% more repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 160

0.29% less ownership

Funds ownership: 94.23% → 93.94% (-0.29%)

17% less call options, than puts

Call options by funds: $267M | Put options by funds: $321M

Holders
498
Holders Change
+46
Holders Change %
+10.18%
% of All Funds
7.26%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.09%
New
96
Increased
167
Reduced
160
Closed
44
Calls
$267M
Puts
$321M
Net Calls
-$54.7M
Net Calls Change
-$24.4M

Top Buyers

1
Norges Bank
Norges Bank
Norway
+$144M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$133M
3
Capital International Investors
Capital International Investors
California
+$83.3M
4
Morgan Stanley
Morgan Stanley
New York
+$68.8M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$48.9M

Top Sellers

1
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$204M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$165M
3
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
-$98.1M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$75.1M
5
Capital World Investors
Capital World Investors
California
-$60.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
MA
476
Montag & Associates
Georgia
$1.34K – – –
CCA
477
Criterion Capital Advisors
Tennessee
$1.34K +$1.19K +7 New
DPW
478
DiNuzzo Private Wealth
Pennsylvania
$1.15K +$1.02K +6 New
LTI
479
Laffer Tengler Investments
Tennessee
$1.15K +$1.02K +6 New
WCM
480
Winthrop Capital Management
Indiana
$1.15K +$1.02K +6 New
PCM
481
Penserra Capital Management
California
$1K – – –
AW
482
Avion Wealth
Texas
$1K +$170 +1 +20%
First Manhattan
483
First Manhattan
New York
$957 +$681 +4 New
DIP
484
DT Investment Partners
Pennsylvania
$901 – – –
Fifth Third Bancorp
485
Fifth Third Bancorp
Ohio
$766 – – –
JFA
486
JNBA Financial Advisors
Minnesota
$766 – – –
Kayne Anderson Rudnick Investment Management
487
Kayne Anderson Rudnick Investment Management
California
$766 – – –
NA
488
NewEdge Advisors
Louisiana
$765 – – –
AWM
489
Abound Wealth Management
Tennessee
$706 +$170 +1 +33%
SIC
490
SJS Investment Consulting
Ohio
$575 -$681 -4 -57%
MCM
491
Manchester Capital Management
Vermont
$575 – – –
MCM
492
MV Capital Management
Maryland
$575 +$511 +3 New
CT
493
Colonial Trust
South Carolina
$394 +$341 +2 New
RCM
494
Raleigh Capital Management
North Carolina
$383 – – –
AWM
495
Able Wealth Management
New Jersey
$383 +$341 +2 New
TWD
496
True Wealth Design
Ohio
$192 – – –
JFGIW
497
Johnson Financial Group Inc (Wisconsin)
Wisconsin
$192 +$170 +1 New
CPG
498
Cornerstone Planning Group
New Jersey
$191 – – –
DWM
499
Dogwood Wealth Management
Kansas
$3 – – –
OAG
500
Orbis Allan Gray
Bermuda
– -$6.76M -38,189 Closed
18 19
20
21 22

ALNY Hedge Fund Activity: Q4 2023 in Review

498 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q4 2023, worth a combined $22.6B — up 8.2% from $20.9B a quarter earlier.

Buyers outnumbered sellers: 96 funds opened new ALNY positions and 44 closed out — a net gain of 52 holders — while 167 added to existing stakes and 160 trimmed.

The largest buyer was Norges Bank, adding an estimated $144M. The largest seller was Baillie Gifford & Co, cutting an estimated $204M.

  • 498 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q4 2023, up from 452 in Q3 2023.
  • Funds reported $22.6B of Alnylam Pharmaceuticals stock for Q4 2023, up 8.2% quarter-over-quarter.
  • 96 funds opened new Alnylam Pharmaceuticals positions in Q4 2023 and 44 closed out, a net change of +52 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q4 2023 was Norges Bank, an estimated $144M added.
  • The largest Alnylam Pharmaceuticals seller in Q4 2023 was Baillie Gifford & Co, an estimated $204M sold.

Based on aggregated 13F filings for Q4 2023.